A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: against (297), hostile (2), resistant (74)

Cisplatin-Pembrolizumab-Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMBROLIZUMAB-PEMETREXED Regimen • N
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Cisplatin-Pembrolizumab-Pemetrexed.pdf

Capecitabine-TrastuzumabIV-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine–Trastuzumab (IV)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (IV)-Tucatini
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-IV-Tucatinib.pdf

Capecitabine-Trastuzumab-SC-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine– Trastuzumab (SC)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (SC)-Tucatinib Indic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-SC-Tucatinib.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlima
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab_400mg (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The t
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description
Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The t
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Atezolizumab(1680-28days)

Description
Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

WRES report and action plan 2023

Description
Workforce Race Equality Standard Annual Report 2023 1 Table of Contents Executive Summary................................................
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/WRES-report-and-action-plan-2023.pdf

Cannabinoid hyperemesis syndrome (CHS) - patient information

Description
This factsheet explains what cannabinoid hyperemesis syndrome is, the symptoms to look out for and how it is treated.
Url
/Media/UHS-website-2019/Patientinformation/Emergency-medicine/Cannabinoid-hyperemesis-syndrome-CHS-2506-PIL.pdf
51 to 60 of 417
Previous … 4 5 6 7 8 … Next